Tuesday, October 19, 2021

Tecentriq approved for first-line metastatic NSCLC




Roche’s checkpoint inhibitor Tecentriq has gained a new approval from the European Commission, for the first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC), its fourth indication in this cancer type.

Specifically, Tecentriq (atezolizumab) has been approved for adults with metastatic NSCLC whose tumours have high PD-L1 expression, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.

The approval is based on data from Roche’s Phase III IMpower110 study which showed that Tecentriq monotherapy improved overall survival (OS) by 7.1 months in patients with high PD-L1 expression.

An updated exploratory OS analysis in the PD-L1 population, presented at the World Conference on Lung Cancer 2020, showed a continued benefit at a median follow-up of 31.3 months.

The median OS in the Tecentriq arm was the same as that observed in the previous analysis – 20.2 months. In the chemotherapy arm, the median OS was found to be 14.7 months.

The safety for Tecentriq in this study was consistent with its known safety profile, with no new safety signal identified. In the Tecentriq-treated population, grade 3-4 treatment-related adverse events were reported in 12.9% of people compared with 44.1% of people receiving chemotherapy.

In a statement, Roche said that Tecentriq is now the first and only single-agent cancer immunotherapy with three dosing options – it can be administered every two, three or four weeks.

“We are delighted to bring Tecentriq to people in the EU with this specific type of lung cancer,” said Levi Garraway, chief medical officer and head of global product development at Roche.

“Tecentriq monotherapy has been shown to improve overall survival in people with high PD-L1 expression, when compared to chemotherapy, and therefore represents a new treatment option for people living with this difficult-to-treat disease,” he added.

Tecentriq is approved across four indications in NSCLC in Europe, including as a single agent or in combination with other targeted therapies and/or chemotherapies.

It was also the first immunotherapy approved for the first-line treatment of adults with extensive-stage small cell lung cancer (SCLC) in combination with chemotherapy (carboplatin and etoposide).



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...